| Outcome |
Relative effect 95%CI |
LoD |
Trt. better when |
|
I2 |
k (RCT/OBS)
|
Bayesian probability
|
Overall ROB
|
Publication bias |
Degree of certainty |
Endpoint importance |
Published MA |
efficacy endpoints 00 |
| deaths (OS) | 0.83 [0.65, 1.06] | | < 1 | | 0% | 1 study (1/-) | 92.9 % | NA | not evaluable | | crucial | - |
| deaths (OS) (extension) | 0.76 [0.53, 1.08] | | < 1 | | 0% | 1 study (1/-) | 93.7 % | NA | not evaluable | | important | - |
| PFS (extension) | 0.72 [0.60, 0.86] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | important | - |
| progression or deaths (PFS) | 0.77 [0.63, 0.94] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | important | - |
| objective responses (ORR) | 0.89 [0.62, 1.27] | | > 1 | | 0% | 1 study (1/-) | 25.9 % | NA | not evaluable | | non important | - |
| objective responses (ORR) (extension) | 1.68 [0.94, 3.01] | | > 1 | | 0% | 1 study (1/-) | 95.9 % | NA | not evaluable | | non important | - |
safety endpoints 00 |
| AE (any grade) | 0.52 [0.27, 1.01] | | < 1 | | 0% | 1 study (1/-) | 97.4 % | NA | not evaluable | | non important | - |
| AE (grade 3-4) | 0.39 [0.27, 0.55] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| AE leading to death (grade 5) | 0.92 [0.39, 2.15] | | < 1 | | 0% | 1 study (1/-) | 57.9 % | NA | not evaluable | | non important | - |
| AE leading to treatment discontinuation (any grade) | 0.34 [0.19, 0.61] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| SAE (any grade) | 0.99 [0.68, 1.44] | | < 1 | | 0% | 1 study (1/-) | 52.0 % | NA | not evaluable | | non important | - |
| STRAE (any grade) | 0.50 [0.29, 0.85] | | < 1 | | 0% | 1 study (1/-) | 99.5 % | NA | not evaluable | | non important | - |
| TRAE (any grade) | 0.27 [0.18, 0.40] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE (grade 3-4) | 0.19 [0.12, 0.29] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| TRAE leading to death (grade 5) | 0.46 [0.02, 13.73] | | < 1 | | 0% | 1 study (1/-) | 67.1 % | NA | not evaluable | | non important | - |
TRAE (grade 3-4) endpoints 00 |
| Colitis TRAE (grade 3-4) | 3.70 [0.17, 82.36] | | < 1 | | 0% | 1 study (1/-) | 20.7 % | NA | not evaluable | | non important | - |
| Hepatitis TRAE (grade 3-4) | 11.47 [1.48, 88.87] | | < 1 | | 0% | 1 study (1/-) | 1.0 % | NA | not evaluable | | non important | - |
| Hyperthyroidism TRAE (grade 3-4) | 0.92 [0.02, 46.51] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Hypothyroidism TRAE (grade 3-4) | 0.92 [0.02, 46.51] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Infusion-related reactions TRAE (grade 3-4) | 0.92 [0.02, 46.51] | | < 1 | | 0% | 1 study (1/-) | 51.6 % | NA | not evaluable | | non important | - |
| Pneumonitis TRAE (grade 3-4) | 3.70 [0.17, 82.36] | | < 1 | | 0% | 1 study (1/-) | 20.7 % | NA | not evaluable | | non important | - |
| Rash TRAE (grade 3-4) | 1.38 [0.23, 8.34] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
AE (grade 3-4) endpoints 00 |
| Anaemia AE (grade 3-4) | 0.08 [0.03, 0.20] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Asthenia AE (grade 3-4) | 0.36 [0.07, 1.89] | | < 1 | | 0% | 1 study (1/-) | 88.5 % | NA | not evaluable | | non important | - |
| Constipation AE (grade 3-4) | 1.38 [0.23, 8.34] | | < 1 | | 0% | 1 study (1/-) | 36.2 % | NA | not evaluable | | non important | - |
| Cough AE (grade 3-4) | 1.84 [0.06, 55.14] | | < 1 | | 0% | 1 study (1/-) | 36.4 % | NA | not evaluable | | non important | - |
| Decreased appetite AE (grade 3-4) | 3.70 [0.17, 82.36] | | < 1 | | 0% | 1 study (1/-) | 20.7 % | NA | not evaluable | | non important | - |
| Diarrhoea AE (grade 3-4) | 0.23 [0.01, 5.09] | | < 1 | | 0% | 1 study (1/-) | 82.1 % | NA | not evaluable | | non important | - |
| Dyspnoea AE (grade 3-4) | 3.70 [0.17, 82.36] | | < 1 | | 0% | 1 study (1/-) | 20.7 % | NA | not evaluable | | non important | - |
| Fatigue AE (grade 3-4) | 0.30 [0.06, 1.51] | | < 1 | | 0% | 1 study (1/-) | 92.7 % | NA | not evaluable | | non important | - |
| Febrile neutropenia AE (grade 3-4) | 0.05 [0.00, 0.86] | | < 1 | | 0% | 1 study (1/-) | 98.0 % | NA | not evaluable | | non important | - |
| Hypertension AE (grade 3-4) | 0.61 [0.10, 3.68] | | < 1 | | 0% | 1 study (1/-) | 70.4 % | NA | not evaluable | | non important | - |
| Increase AST AE (grade 3-4) | 4.66 [0.54, 40.17] | | < 1 | | 0% | 1 study (1/-) | 8.2 % | NA | not evaluable | | non important | - |
| Increased ALT AE (grade 3-4) | 4.66 [0.54, 40.17] | | < 1 | | 0% | 1 study (1/-) | 8.2 % | NA | not evaluable | | non important | - |
| Leucopenia AE (grade 3-4) | 0.23 [0.03, 2.05] | | < 1 | | 0% | 1 study (1/-) | 90.5 % | NA | not evaluable | | non important | - |
| Nausea AE (grade 3-4) | 0.18 [0.02, 1.56] | | < 1 | | 0% | 1 study (1/-) | 93.9 % | NA | not evaluable | | non important | - |
| Neutropenia AE (grade 3-4) | 0.03 [0.01, 0.14] | | < 1 | | 0% | 1 study (1/-) | 100.0 % | NA | not evaluable | | non important | - |
| Pancytopenia (AE grade 3-4) | 0.46 [0.04, 5.08] | | < 1 | | 0% | 1 study (1/-) | 73.6 % | NA | not evaluable | | non important | - |
| Pneumonia AE (grade 3-4) | 0.71 [0.26, 1.93] | | < 1 | | 0% | 1 study (1/-) | 75.0 % | NA | not evaluable | | non important | - |
| Pyrexia AE (grade 3-4) | 0.46 [0.02, 13.73] | | < 1 | | 0% | 1 study (1/-) | 67.1 % | NA | not evaluable | | non important | - |
| Sepsis AE (grade 3-4) | 0.46 [0.04, 5.08] | | < 1 | | 0% | 1 study (1/-) | 73.6 % | NA | not evaluable | | non important | - |
| Thrombocytopenia AE (grade 3-4) | 0.05 [0.01, 0.34] | | < 1 | | 0% | 1 study (1/-) | 99.9 % | NA | not evaluable | | non important | - |
| Vomiting AE (grade 3-4) | 0.46 [0.04, 5.08] | | < 1 | | 0% | 1 study (1/-) | 73.6 % | NA | not evaluable | | non important | - |
